Should Value Investors Buy Teleflex (TFX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
TFX vs. SONVY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Teleflex (TFX) and SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?
Teleflex Incorporated (TFX) Q2 2025 Earnings Conference Call Transcript
Teleflex Incorporated (NYSE:TFX ) Q2 2025 Earnings Call July 31, 2025 8:00 AM ET Company Participants John R. Deren - Executive VP & CFO Lawrence Soren Keusch - Vice President of Investor Relations & Strategy Development Liam J.
Compared to Estimates, Teleflex (TFX) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Teleflex (TFX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Teleflex (TFX) Q2 Earnings and Revenues Top Estimates
Teleflex (TFX) came out with quarterly earnings of $3.73 per share, beating the Zacks Consensus Estimate of $3.36 per share. This compares to earnings of $3.42 per share a year ago.
Analysts Estimate Teleflex (TFX) to Report a Decline in Earnings: What to Look Out for
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex Q1 Earnings Beat, '25 EPS View Down, Stock Up
TFX benefits from a diversified product portfolio in the first quarter of 2025, with strength in the Surgical and Interventional segments.
Teleflex Incorporated (TFX) Q1 2025 Earnings Call Transcript
Teleflex Incorporated (NYSE:TFX ) Q1 2025 Results Conference Call May 1, 2025 8:00 AM ET Company Participants Lawrence Keusch - VP-IR & Strategy Development Liam Kelly - Chairman, President & Chief Executive Officer John Deren - Executive VP & Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley Michael Sarcone - Jefferies Jayson Bedford - Raymond James Vikramjeet Singh Chopra - Wells Fargo Matthew O'Brien - Piper Sandler Anthony Petrone - Mizuho Group Shagun Singh - RBC Richard Newitter - Truist Securities Craig Bijou - Bank of America Michael Polark - Wolfe Research Mike Matson - Needham Operator Good morning, ladies and gentlemen, and welcome to the Teleflex First Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded, and we will be available on the company's website for replay shortly.
Here's What Key Metrics Tell Us About Teleflex (TFX) Q1 Earnings
While the top- and bottom-line numbers for Teleflex (TFX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Teleflex (TFX) Tops Q1 Earnings and Revenue Estimates
Teleflex (TFX) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.88 per share. This compares to earnings of $3.21 per share a year ago.
Earnings Preview: Teleflex (TFX) Q1 Earnings Expected to Decline
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex Announces Split Into 2 Public Companies
Teleflex's (TFX 2.89%) fourth-quarter 2024 earnings conference call, held on February 27, 2025, revealed significant strategic shifts for the medical device company. In a transformative announcement, Teleflex outlined plans to acquire the Vascular Intervention business from Biotronik and separate into two publicly traded companies.
